Dengue Fever Clinical, Companies, Therapeutic Assessment, Therapies, Treatment Algorithm, Pipeline Analysis | Johnson & Johnson, Novartis Pharmaceuticals, Merck Sharp & Dohme LLC, Panacea Biotec, Codagenix

Dengue Fever Pipeline constitutes 8+ key companies continuously working towards developing 10+ Dengue Fever treatment therapies, analyzes DelveInsight.

Dengue Fever Overview:

Dengue fever is a viral illness transmitted by Aedes mosquitoes, primarily Aedes aegypti. It is widespread in tropical and subtropical regions, particularly in Southeast Asia, the Pacific Islands, the Caribbean, and Central and South America. The infection usually begins suddenly with high fever, intense headache, pain behind the eyes, joint and muscle aches, skin rash, and mild bleeding signs such as gum or nose bleeding and easy bruising. Symptoms generally develop 4-10 days after a mosquito bite and last about 2-7 days.

The severity of dengue can range from mild illness to life-threatening forms. Severe dengue, which includes dengue hemorrhagic fever (DHF) and dengue shock syndrome (DSS), is marked by severe abdominal pain, persistent vomiting, rapid breathing, gum bleeding, extreme fatigue, restlessness, and the presence of blood in vomit or stool. Without timely management, these complications can lead to shock, organ failure, and death. Children and individuals experiencing a second dengue infection face a greater risk of progressing to severe disease.

Currently, there is no specific antiviral therapy for dengue; treatment is supportive, focusing on relieving symptoms and maintaining proper fluid balance. Prevention plays a critical role and involves minimizing mosquito exposure through insect repellents, protective clothing, and removal of standing water where mosquitoes breed. Vaccination is also being explored-Dengvaxia, the first dengue vaccine, has been approved in some endemic regions but is recommended only for individuals with a prior dengue infection, as use in dengue-naïve individuals may increase the risk of severe disease. Effective mosquito control measures and public health interventions remain essential to reducing transmission and preventing outbreaks.

Request for a detailed insights report on Dengue Fever pipeline insights https://www.delveinsight.com/report-store/dengue-fever-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

"Dengue Fever Pipeline Insight 2025" report by DelveInsight provides a comprehensive analysis of the ongoing clinical development activities and growth prospects across the Dengue Fever Therapeutics Market.

Key Takeaways from the Dengue Fever Pipeline Report

DelveInsight's Dengue Fever pipeline report depicts a robust space with 200+ active players working to develop 200+ pipeline therapies for Dengue Fever treatment.
In June 2025, Merck (MSD) launched MOBILIZE-1, the first Phase III clinical trial for its investigational single-dose, quadrivalent dengue vaccine candidate (V181). This randomized, double-blind, placebo-controlled study has begun enrollment, with the first participants recruited in Singapore and aiming to enroll ~12,000 children aged 2-17 across 30+ dengue-endemic sites in the Asia-Pacific region.
Key Dengue Fever companies such as Johnson & Johnson, Novartis Pharmaceuticals, Merck Sharp & Dohme LLC, Panacea Biotec, Codagenix, and others are evaluating new drugs for Dengue Fever to improve the treatment landscape.
Promising Dengue Fever pipeline therapies in various stages of development include V181, EYU-688, and others.

Dengue Fever Pipeline Analysis
The report provides insights into:
The report provides detailed insights into the key companies that are developing therapies in the Dengue Fever Market.
The report also evaluates different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Dengue Fever treatment.
It analyzes the key companies involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
It navigates the emerging drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement, and financing details for future advancement of the Dengue Fever market.

Download our free sample page report on Dengue Fever pipeline insights https://www.delveinsight.com/sample-request/dengue-fever-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Dengue Fever Emerging Drugs

V181 - Merck Sharp & Dohme LLC

V181 is an experimental quadrivalent dengue vaccine being developed by Merck & Co. to protect against dengue fever, a mosquito-borne illness common in tropical and subtropical regions. The vaccine uses purified inactivated virus (PIV) technology, similar to that used in inactivated vaccines for other viral infections, designed to trigger a strong immune response without causing disease. Early data indicates that V181 generates a balanced immune response against all four dengue virus serotypes, with the goal of preventing both infection and severe complications such as dengue hemorrhagic fever. The candidate is currently in Phase II clinical development.
EYU-688 - Novartis Pharmaceuticals

EYU-688 is an oral small-molecule therapy under development by Novartis for dengue fever. It works by targeting nonstructural protein 4B (NS4B), essential for viral replication, along with the somatostatin receptor (SSTR). The drug is presently in the Phase II stage of clinical trials for dengue treatment.

Dengue Fever Companies

There are nearly 8 or more key pharmaceutical companies engaged in developing therapies for Dengue Fever. Among them, the most advanced candidates are currently in Phase II clinical development, with Merck Sharp & Dohme LLC and Novartis Pharmaceuticals leading the way.

Request the Sample PDF to Get Detailed Insights About the Dengue Fever Pipeline Reports Offerings https://www.delveinsight.com/report-store/dengue-fever-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

DelveInsight's report covers around 75+ products under different phases of clinical development like

Late stage products (Phase III)
Mid-stage products (Phase II)
Early-stage product (Phase I) along with the details of
Pre-clinical and Discovery stage candidates
Discontinued & Inactive candidates

Dengue Fever pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

Intravenous
Subcutaneous
Oral
Intramuscular

Dengue Fever Products have been categorized under various Molecule types such as

Monoclonal antibody
Small molecule
Peptide

Download Sample Pages to Get an in-depth Assessment of the Emerging Dengue Fever Therapies and Key Companies: Dengue Fever Clinical Trials and advancements https://www.delveinsight.com/report-store/dengue-fever-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Dengue Fever Pipeline Therapeutic Assessment
• Dengue Fever Assessment by Product Type
• Dengue Fever By Stage
• Dengue Fever Assessment by Route of Administration
• Dengue Fever Assessment by Molecule Type

Download Dengue Fever Sample report to know in detail about the Dengue Fever treatment market @ Dengue Fever Therapeutic Assessment https://www.delveinsight.com/sample-request/dengue-fever-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Trending Reports By DelveInsight:

Functional Constipation Market
https://www.delveinsight.com/report-store/chronic-constipation-market

Leber's Hereditary Optic Neuropathy Market https://www.delveinsight.com/report-store/lebers-hereditary-optic-neuropathy-lhon-market

Gastric Neuroendocrine Tumors Market
https://www.delveinsight.com/report-store/gastric-neuroendocrine-tumors-market

Immune Thrombocytopenic Purpura Market
https://www.delveinsight.com/report-store/immune-thrombocytopenia-itp-market

Visceral Pain Associated With GI Disorders Market
https://www.delveinsight.com/report-store/visceral-pain-associated-with-gi-disorders-market

Bullous Pemphigoid Market
https://www.delveinsight.com/report-store/bullous-pemphigoid-market

Cyclin-dependent Kinase-like 5 Deficiency Disorder Market https://www.delveinsight.com/infographics/cyclin-dependent-kinase-like-5-cdkl5-deficiency-disorder-market

Myocarditis Market
https://www.delveinsight.com/report-store/myocarditis-market

Recurrent Blood Clots Market
https://www.delveinsight.com/report-store/recurrent-blood-clots-thrombophilia-market

Zollinger-ellison Syndrome Market
https://www.delveinsight.com/report-store/zollinger-ellison-syndrome-market

Age-related Hearing Loss Medical Device Market
https://www.delveinsight.com/blog/age-related-hearing-loss-device-market

Heart Sounds Sensors Market
https://www.delveinsight.com/report-store/heart-sounds-sensors-electronic-stethoscope-market

Hypoplastic Left Heart Syndrome Market
https://www.delveinsight.com/report-store/hypoplastic-left-heart-syndrome-market

Infectious Arthritis/Septic Arthritis Market
https://www.delveinsight.com/report-store/infectious-arthritisseptic-arthritis-market

Plasmacytoma Market
https://www.delveinsight.com/report-store/plasmacytoma-market

Agoraphobia Market
https://www.delveinsight.com/report-store/agoraphobia-market

Clinically Isolated Syndrome Market
https://www.delveinsight.com/report-store/clinically-isolated-syndrome-cis-market

Fucosidosis Market
https://www.delveinsight.com/report-store/fucosidosis-market

Major Depressive Disorder Market
https://www.delveinsight.com/report-store/major-depressive-disorder-market

Neuronal Ceroid-lipofuscinoses Market
https://www.delveinsight.com/report-store/neuronal-ceroid-lipofuscinoses-cln1-disease-market

Orthotic Devices Market
https://www.delveinsight.com/report-store/orthotic-devices-market

Contact Info:
Kritika Rehani
krehani@delveinsight.com
info@delveinsight.com
+14699457679

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

This release was published on openPR.